News

The CHMP will recommend SB15, biosimilar to aflibercept (Eylea), for marketing authorisation by the European Commission

Yousif Subhi, MD, PhD, discusses his Ophthalmologica Lecture, "Things That Matter: An Evidence-Based Approach to AMD and CSC"

Yousif Subhi, MD, PhD, delivered the Ophthalmologica Lecture, "Things That Matter: An Evidence-Based Approach to AMD and CSC."

We spoke with Andrea Govetto, MD, PhD, winner of the inaugural Ramin Tadayoni Award at EURETINA

The data were presented at the Keystone Symposium Targeting Dry Age-related Macular Degeneration: Pathophysiology and Emerging Therapies.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

Robert Osher, MD, sat down with David Hutton of Ophthalmology Times to discuss the Lifetime Achievement award he received from the European Society of Cataract and Refractive Surgeons.

Veeral S. Sheth, MD, MBA, FASRS, FACS, discussed the outcome of the Phase 1 HELIOS trial of OTX-TKI at from this year's EURETINA congress being held in Barcelona, Spain, which takes place September 19-22, 2024.

We spoke with Andrea Govetto, MD, PhD, winner of the inaugural Ramin Tadayoni Award at EURETINA

Efferocytosis’ role in retinopathy is largely unknown despite knowledge of the process in other diseases.

Researchers in Portugal investigated Usher syndrome, Senior-Loker syndrome and other ciliopathies

Why having a set process for diagnostic imaging is crucial to patient outcomes

Socioeconomic factors have long been a looming issue in various health outcomes. A team of researchers from Shanghai Jiao Tong University School of Medicine and Fudan University set out to review the impact of socioeconomic status inequality on the incidence of AMD.

American Academy of Ophthalmology offers in-person and virtual options for annual meeting, Subspecialty Day.

Zhang’s journey as the first retina optometrist in Colorado

Bothnia Dystrophy generally presents during early childhood; patients have night blindness, progressive visual loss, and subsequent legal blindness.

Bothnia Dystrophy generally presents during early childhood; patients have night blindness, progressive visual loss, and subsequent legal blindness.

A case series illuminates neuro-ophthalmologic manifestations, retinal vascular involvement and other pathologies

Depending on results from the survey for healthcare professionals, a scope expansion for eIFUs could impact ophthalmic devices including contact lenses.

The PPQ campaign consisted of the production of 3 successful consecutive commercial-scale drug substance batches required for the validation of Opthea’s manufacturing process.

Oral gildeuretinol demonstrated a clinically meaningful reduction in the GA lesion growth rate at 24 months in the SAGA study.

Oral gildeuretinol demonstrated a clinically meaningful reduction in the geographic atrophy lesion growth rate at 24 months, supporting additional clinical development. SAGA topline data has been accepted as a late breaker at the 128th annual meeting of the American Academy of Ophthalmology, being held October 18-21 in Chicago.

Cutting-edge approaches for MDs and ODs

The research team used spectral-domain OCT and OCT angiography imaging to study the changes in the retinal microvasculature in patients

4D Molecular Therapeutics has announced data based on the longest interim follow-up from Phase 1/2 PRISM clinical trial and 4FRONT Phase 3 study design.

According to a team of researchers at the National Institutes of Health, their findings in animals suggest a surgery-free treatment for cataracts.

Ripple will lead preclinical development of RTC-620 while AbbVie will lead the clinical and commercialization activities upon exercise of option-to-license agreement.